CTOs on the Move

Agrinos

www.agrinos.com

 
Agrinos is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture worldwide. Our products help farmers by providing increased crop yield and productivity, improved crop quality, enhanced efficiency of conventional fertilizer and a reduced environmental footprint.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.agrinos.com
  • 279 Cousteau Place Suite 100
    Davis, CA USA 95618
  • Phone: 888.706.9505

Executives

Name Title Contact Details

Similar Companies

Vitalcor

Vitalcor is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quad Five Materials Bio

Quad Five Materials Bio is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma BioSource Inc

Pharma BioSource Inc is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Nuvalent

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.